Pemetrexed Disodium for Injection
Sponsors
Jiangsu HengRui Medicine Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., BeBetter Med Inc, Nanjing Leads Biolabs Co.,Ltd
Conditions
Advanced Solid TumorsAdvanced Solid TumourAdvanced Urothelial CarcinomaEGFRMetastatic Cervical CancerNSCLC (Advanced Non-small Cell Lung Cancer)NSCLC Patients With Brain MetastasisNon Small Cell Lung Cancer
Phase 1
A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors
NCT06116240
Start: 2022-09-02End: 2023-12-31Target: 135Updated: 2023-11-03
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
RecruitingNCT06474455
Start: 2024-07-02End: 2029-12-01Target: 156Updated: 2026-05-11
Phase 2
Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
Not yet recruitingNCT06514027
Start: 2024-07-31End: 2027-11-30Target: 30Updated: 2024-07-23
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
RecruitingNCT06783647
Start: 2025-06-11End: 2026-12-24Target: 230Updated: 2026-05-18
Phase 3
Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)
NCT04203485
Start: 2020-06-15End: 2022-05-31Target: 762Updated: 2020-05-08
A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma
RecruitingNCT06738251
Start: 2025-02-12End: 2027-09-30Target: 402Updated: 2025-07-17
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
RecruitingNCT06956001
Start: 2024-11-19End: 2028-07-01Target: 300Updated: 2026-02-12
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
RecruitingNCT06970639
Start: 2024-09-26End: 2029-09-01Target: 380Updated: 2026-02-12
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
RecruitingNCT07418749
Start: 2026-03-30End: 2028-12-01Target: 398Updated: 2026-04-06